Benefits of Retained Insulin secretion for Good HealTh (BRIGHT)
Research type
Research Study
Full title
Understanding the impact of endogenous insulin secretion on clinical outcomes in type 1 diabetes and the optimal approach to C-peptide measurement for outcome prediction
IRAS ID
347042
Contact name
Angus Jones
Contact email
Sponsor organisation
Royal Devon University Healthcare NHS Foundation Trust
Duration of Study in the UK
1 years, 10 months, 30 days
Research summary
The purpose of this research is to understand the impact of retained endogenous insulin (as measured by C-peptide) on quality of life and related outcomes in people living with insulin treated diabetes, and, in those living with type 1 diabetes, to determine the pragmatic and non-pragmatic C-peptide measures which have the strongest association with clinical benefit (including repeated home samples and derived measures of beta cell function). We will do this in two ways:
Firstly, we will extend a large existing prospective study of new adult onset diabetes (StartRight https://clinicaltrials.gov/ct2/show/NCT03737799) which has followed 1800 participants for median 4 years from diabetes diagnosis. Participants with insulin treated diabetes will be invited to take part in a further research visit remotely or face to face. We will assess the longitudinal relationship between C-peptide and the available quality of life, mental health status and healthcare utilization measures over up to 9 years from diabetes diagnosis and assess additional measures in cross sectional analysis.
In the second part of this research, we will utilize cohorts of over 2500 participants with T1D, measured C-peptide and consent to recontact to recruit 200 participants with a range of C-peptide. Eligible participants with C-peptide measured in clinical care may also be invited to take part. We will undertake detailed assessment of complex and pragmatic measures of C-peptide and beta cell function and compare performance in predicting glycaemic outcomes (using data from continuous glucose monitors) and (where relevant) patient reported outcomes.REC name
London - Stanmore Research Ethics Committee
REC reference
25/PR/0929
Date of REC Opinion
5 Aug 2025
REC opinion
Further Information Favourable Opinion